CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing a novel cancer treatment by repurposing Disulfiram, an existing drug, to target cancer stem cells. By encapsulating it in liposomes, the project aims to enhance its effectiveness and reduce toxicity, paving the way for clinical trials in breast and liver cancer.
Most cancers remain ‘incurable’ and life-thretening.
Cancer stem cells (CSCs) are the source of chemo/radioresistance and responsible for cancer recurrence which suggests the urgent requirement of CSC-targeting drugs.
Drug development is a slow (15 years/drug) and costly (US$1.5bn/drug) procedure with only 5-25% of new oncology drugs in clinical development actually reaching the market mainly due to the toxicity of novel molecules.
This dilemma has led to an increasing appreciation of the potent…
Fourth Military Medical University
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
